News >

GI Oncologist Sheds Light on Present and Future of mCRC Treatment

Brandon Scalea
Published: Thursday, Mar 21, 2019

Amit Mahipal, MBBS

Amit Mahipal, MBBS

Unless they have a rare genetic alteration, patients with metastatic colorectal cancer (mCRC) should be treated with a chemotherapy backbone and a biologic agent in the frontline setting, said Amit Mahipal, MBBS.

Most patients in the United States will receive FOLFOX with either the VEGF inhibitor bevacizumab (Avastin) or an EGFR-targeted monoclonal antibody, typically cetuximab (Erbitux) or panitumumab (Vectibix), said Mahipal, a professor of medicine at the Mayo Clinic.

Moreover, highly effective targeted therapies are emerging for biomarkers such as BRAF, HER2, RAS, and NTRK. For the rare subset of patients with microsatellite instability high (MSI-H) tumors, immunotherapy both as a single agent and in combination has become a reasonable treatment option and there are ongoing trials attempting to expand the reach of this approach in mCRC.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication